Skip to content
Relatix Health

Relatix Health

Radically different

  • Participate
    • Start here
  • Services
    • Tests to participate in
  • Resources
  • About
    • Our Vision – A radically different future
    • Our mission – personalised lifelong support
    • News
    • FAQ
    • Contact
    • Trust and Privacy
    • Support us
  • Log in / Sign up
Posted on July 6, 2026 by admin

Oral and Sublingual Ketamine

Conditions: Major Depression Severe

Interventions: Drug: 75 mg of oral ketamine; Drug: Sublingual ketamine 75 mg

Sponsors: Western University, Canada

Not yet recruiting
CategoriesClinicalTrials.gov TagsCanada, Depression, Mood and emotional regulation

Post navigation

Previous PostPrevious Email-Delivered Digital Positive Affect Intervention for Young Adults in Zimbabwe
Next PostNext Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium – Maintenance
Relatix Health

Relatix Health helps people understand their minds, explore relevant support and take part in research on their own terms. We connect lived experience with responsible research while protecting privacy, dignity and choice.

For researchers, clinicians and organisations, visit our sister site, Relatix Bio.

Take part

Start here Participate Tests to participate in Log in or sign up

Find support

Resources Services FAQ I need help now

Our commitments

Our Vision Our Mission Trust and Privacy

About

About us News Support us Contact

© 2026 Relatix Health. All rights reserved.